Tema Etfs LLC Makes New Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Tema Etfs LLC purchased a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 12,435 shares of the company’s stock, valued at approximately $266,000. Tema Etfs LLC owned approximately 0.08% of Jasper Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also bought and sold shares of the business. Boxer Capital Management LLC bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $7,483,000. Integral Health Asset Management LLC boosted its holdings in shares of Jasper Therapeutics by 85.7% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $13,897,000 after purchasing an additional 300,000 shares during the last quarter. Braidwell LP boosted its holdings in shares of Jasper Therapeutics by 47.9% during the 4th quarter. Braidwell LP now owns 714,658 shares of the company’s stock valued at $15,279,000 after purchasing an additional 231,358 shares during the last quarter. Stempoint Capital LP bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $2,892,000. Finally, T. Rowe Price Investment Management Inc. bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $1,757,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Trading Up 1.2%

Shares of NASDAQ:JSPR opened at $4.93 on Monday. Jasper Therapeutics, Inc. has a 12 month low of $3.13 and a 12 month high of $26.84. The company has a 50-day moving average price of $4.60 and a 200 day moving average price of $10.86. The company has a market cap of $74.06 million, a price-to-earnings ratio of -1.04 and a beta of 2.74.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24). As a group, equities analysts forecast that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on JSPR shares. UBS Group dropped their price objective on shares of Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Oppenheimer dropped their price objective on shares of Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating for the company in a report on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $62.22.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.